New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTPRGO, MYL, VRX, ENDPPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Check below for free stories on ENDP;MYL;PRGO;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 19, 2014
11:44 EDTMYLMylan launches generic Precedex Injection
Subscribe for More Information
August 18, 2014
15:59 EDTVRXAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
10:06 EDTMYLLannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
August 15, 2014
17:03 EDTVRXValeant extends offer to acquire Allergan
Valeant Pharmaceuticals (VRX) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31. The exchange offer was previously scheduled to expire August 15. All other terms and conditions of the exchange offer remain unchanged.
14:14 EDTVRXValeant being probed by IRS after Biovail deal, FT says
Subscribe for More Information
10:01 EDTPRGOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:45 EDTVRXEvent-driven funds, Pershing own over 20% of Allergan, CNBC reports
Event-driven hedge funds and Pershing Square owned over 20% of Allergan as of June 30, CNBC's David Faber reports. Valeant (VRX) and Pershing are seen as getting the over 30% to call a special meeting, Faber adds.
07:22 EDTPRGOPerrigo upgraded at B. Riley
As previously reported, B. Riley upgraded Perrigo to Buy from Neutral. The firm upgraded shares following the better than expected Q4 report and guidance and said it expects a return to consistent financial performance.
06:04 EDTPRGOPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
August 14, 2014
17:41 EDTVRXPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
14:28 EDTVRXAckman says Pershing, Valeant took no tender steps before buying Allergan shares
Bill Ackman made the statement to CNBC's Scott Wapner regarding his fund and Valeant's (VRX) pursuit of Allergan (AGN). Note that the Wall Street Journal reported earlier that the SEC is investigating Valeant and Pershing's pursuit of Allergan.
13:48 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, WSJ says
Subscribe for More Information
13:22 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
10:06 EDTPRGOPerrigo sees FY15 revenue growth 7%-11%
Perrigo in earnings call presentation slides guided its FY15 revenue growth to 7%-11% above FY14. The company sees adjusted operating margin around 29% with an effective tax rate around 16%. Perrigo expects operating cash flow greater than $1B.
09:11 EDTPRGOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:55 EDTPRGOPerrigo reports Q4 Consumer Healthcare sales $606.9M
Subscribe for More Information
07:55 EDTPRGOPerrigo sees FY15 adjusted EPS $7.20-$7.50, consensus $7.53
Subscribe for More Information
07:54 EDTPRGOPerrigo reports Q4 adjusted gross margin 44.5%
Subscribe for More Information
07:53 EDTPRGOPerrigo reports Q4 adjusted EPS $1.74 consensus $1.55
Subscribe for More Information
07:46 EDTENDPEndo valuation attractive, says Goldman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use